Drupal.behaviors.print = function(context) {window.print();window.close();}>
Prostate Cancer Prognostic Test Maker Aureon Biosciences Closes Shop
October 12, 2011
Prostate Cancer Prognostic Test Maker Aureon Biosciences Closes Shop
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
Prostate Cancer MDx Competition Heating Up; New Data from Genomic Health, Myriad
May 15, 2013 / Pharmacogenomics Reporter
With 8 Percent Revenue Bump in Q1, Genomic Health Focus on Expanding Oncotype DX Franchise
May 8, 2013 / Pharmacogenomics Reporter
Wall Street Closely Tracking Validation Data on Genomic Health's Oncotype DX Prostate Cancer Test
April 3, 2013 / Pharmacogenomics Reporter
After 14 Percent Revenue Bump in 2012, Genomic Health Focusing on Market Growth, Prostate Dx Launch
February 13, 2013 / Pharmacogenomics Reporter
Genomic Health Attributes Q3 Revenue Growth to Strong International Test Adoption
November 14, 2012 / Pharmacogenomics Reporter